Daiichi Sankyo Company, Limited

Daiichi Pharmaceutical Co., Ltd.

Masaki Setoguchi

Kiyoshi Nakayama

Yuichi Tominaga

Kazuyuki Sugita

Takashi Odagiri

Masanori Saitou

Toru Taniguchi

Keisuke Yoshida

Atsushi Nakayama

Shoko Yoshida

Yuuichi Sugimoto

Kouichi Uoto

Nobuo Machinaga

Yoshiyuki Yoneda

Masaki Miyazaki

Akitake Yamaguchi

Takanori Wakabayashi

A compound that inhibits interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity is provided. The present invention provides a dispiropyrrolidine derivative represented by the following formula (1), which has various substituents, inhibits interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity, wherein R, R, R, ring A, and ring B in formula (1) respectively have the same meanings as defined in the specification. 

Dispiropyrrolidine derivatives

There is provided a novel compound that inhibits phosphatidylinositol 3-kinase (PI3K) and/or the mammalian target of rapamycin (mTOR) and exhibits anti-tumor activity. The present invention provides a compound represented by the following formula (1) having various substituents that inhibits PI3K and/or mTOR and exhibits anti-tumor activity: wherein R, R, R, R, R, R, R, and X each have the same meaning as defined in the specification.

Morpholinopurine derivatives

This invention provides an industrially useful process for producing 1,4-transcyclohexanecarboxylic acid derivative (1) which has excellent VLA-4 inhibitory action and safety, and an intermediate which is useful in such method. More particularly, this invention relates to a process for converting a compound of formula (I) into a compound of formula (VI) by the reaction scheme: 

Process for producing pyrrolidine derivative

Growing community of inventors

Tokyo, Japan

Masaki Setoguchi